Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 149014, 14 pages
http://dx.doi.org/10.1155/2015/149014
Review Article

Colorectal Cancer Biomarkers: Where Are We Now?

1Department of Gastrointestinal Oncology and Genetics, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR 00927-6346, USA
2UPR-MDACC Partnership for Excellence in Cancer Research Program, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936-5067, USA
3Department of Medicine, Biochemistry, and Surgery, University of Puerto Rico School of Medicine, San Juan, PR 00936-5067, USA

Received 8 September 2014; Accepted 19 February 2015

Academic Editor: Mario Scartozzi

Copyright © 2015 Maria Gonzalez-Pons and Marcia Cruz-Correa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cancer Institute, SEER Cancer Statistics Factsheets: Colon and Rectum Cancer, National Cancer Institute, Bethesda, Md, USA, http://seer.cancer.gov/statfacts/html/colorect.html.
  2. American Cancer Society, Colorectal Cancer Facts & Figures 2014–2016, American Cancer Society, Atlanta, Ga, USA, 2014.
  3. R. W. Burt, D. T. Bishop, H. T. Lynch, P. Rozen, and S. J. Winawer, “Risk and surveillance of individuals with heritable factors for colorectal cancer,” Bulletin of the World Health Organization, vol. 68, no. 5, pp. 655–665, 1990. View at Google Scholar · View at Scopus
  4. S. J. Winawer, R. H. Fletcher, L. Miller et al., “Colorectal cancer screening: clinical guidelines and rationale,” Gastroenterology, vol. 112, no. 2, pp. 594–642, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Kumar, “Biomarkers of disease in medicine,” in Current Trends in Science, pp. 403–417, Indian Academy of Sciences, 2009. View at Google Scholar
  6. Z. Huang, D. Huang, S. Ni, Z. Peng, W. Sheng, and X. Du, “Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer,” International Journal of Cancer, vol. 127, no. 1, pp. 118–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. I. Parikh and R. S. Vasan, “Assessing the clinical utility of biomarkers in medicine,” Biomarkers in Medicine, vol. 1, no. 3, pp. 419–436, 2007. View at Publisher · View at Google Scholar
  8. T. Tanaka, M. Tanaka, and R. Ishigamori, “Biomarkers for colorectal cancer,” International Journal of Molecular Sciences, vol. 11, no. 9, pp. 3209–3225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. F. Kane, M. Loda, G. M. Gaida et al., “Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines,” Cancer Research, vol. 57, no. 5, pp. 808–811, 1997. View at Google Scholar · View at Scopus
  10. J. R. Jass, M. D. Walsh, M. Barker, L. A. Simms, J. Young, and B. A. Leggett, “Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability,” European Journal of Cancer, vol. 38, no. 7, pp. 858–866, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Roth, S. Tejpar, M. Delorenzi et al., “Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 466–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Iacopetta, F. Grieu, and B. Amanuel, “Microsatellite instability in colorectal cancer,” Asia-Pacific Journal of Clinical Oncology, vol. 6, no. 4, pp. 260–269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Gryfe, H. Kim, E. T. K. Hsieh et al., “Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer,” The New England Journal of Medicine, vol. 342, no. 2, pp. 69–77, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Popat, R. Hubner, and R. S. Houlston, “Systematic review of microsatellite instability and colorectal cancer prognosis,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 609–618, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. A. Sinicrope, R. L. Rego, K. C. Halling et al., “Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients,” Gastroenterology, vol. 131, no. 3, pp. 729–737, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Benatti, R. Gafà, D. Barana et al., “Microsatellite instability and colorectal cancer prognosis,” Clinical Cancer Research, vol. 11, no. 23, pp. 8332–8340, 2005. View at Google Scholar
  17. S. R. Brown, P. J. Finan, N. R. Hall, and D. T. Bishop, “Incidence of DNA replication errors in patients with multiple primary cancers,” Diseases of the Colon & Rectum, vol. 41, no. 6, pp. 765–769, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Shitoh, F. Konishi, Y. Miyakura, K. Togashi, T. Okamoto, and H. Nagai, “Microsatellite instability as a marker in predicting metachronous multiple colorectal carcinomas after surgery: a cohort-like study,” Diseases of the Colon and Rectum, vol. 45, no. 3, pp. 329–333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. W.-S. Jo and J. M. Carethers, “Chemotherapeutic implications in microsatellite unstable colorectal cancer,” Cancer Biomarkers, vol. 2, no. 1-2, pp. 51–60, 2006. View at Google Scholar · View at Scopus
  20. R. Jover, A. Castells, X. Llor, and M. Andreu, “Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer,” Gut, vol. 55, no. 12, pp. 1819–1820, 2006. View at Google Scholar · View at Scopus
  21. C. Guastadisegni, M. Colafranceschi, L. Ottini, and E. Dogliotti, “Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data,” European Journal of Cancer, vol. 46, no. 15, pp. 2788–2798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Ribic, D. J. Sargent, M. J. Moore et al., “Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer,” The New England Journal of Medicine, vol. 349, no. 3, pp. 247–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton et al., “Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1814–1821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Fallik, F. Borrini, V. Boige et al., “Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer,” Cancer Research, vol. 63, no. 18, pp. 5738–5744, 2003. View at Google Scholar · View at Scopus
  25. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-Y. Douillard, K. S. Oliner, S. Siena et al., “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. W. de Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Aprile, M. Macerelli, M. De, S. Pizzolitto, and G. Fasola, “The relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients,” OA Molecular Oncology, vol. 1, no. 1, article 7, 2013. View at Publisher · View at Google Scholar
  29. D. Kislitsin, A. Lerner, G. Rennert, and Z. Lev, “K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes,” Digestive Diseases and Sciences, vol. 47, no. 5, pp. 1073–1079, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Downward, “Targeting RAS signalling pathways in cancer therapy,” Nature Reviews Cancer, vol. 3, no. 1, pp. 11–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. W. D. Roock, V. D. Vriendt, N. Normanno, F. Ciardiello, and S. Tejpar, “KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer,” The Lancet Oncology, vol. 12, no. 6, pp. 594–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. W. S. Samowitz, K. Curtin, D. Schaffer, M. Robertson, M. Leppert, and M. L. Slattery, “Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study,” Cancer Epidemiology, Biomarkers & Prevention, vol. 9, no. 11, pp. 1193–1197, 2000. View at Google Scholar · View at Scopus
  33. H. J. Andreyev, A. R. Norman, D. Cunningham et al., “Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study,” British Journal of Cancer, vol. 85, no. 5, pp. 692–696, 2001. View at Google Scholar
  34. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. W. de Roock, H. Piessevaux, J. de Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508–515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Lievre, J. B. Bachet, V. Boige et al., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar
  37. G. Wang, R. K. Kelley, and GAPPNet, “KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic,” PLOS Currents, vol. 2, Article ID RRN1175, 2010. View at Publisher · View at Google Scholar
  38. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar
  39. H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, “RAF/RAS oncogenes and mismatch-repair status,” Nature, vol. 418, article 934, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. A. de la Chapelle, G. Palomaki, and H. Hampel, “Identifying lynch syndrome,” International Journal of Cancer, vol. 125, no. 6, pp. 1492–1493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Domingo, P. Laiho, M. Ollikainen et al., “BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing,” Journal of Medical Genetics, vol. 41, no. 9, pp. 664–668, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. M. B. Loughrey, P. M. Waring, A. Tan et al., “Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer,” Familial Cancer, vol. 6, no. 3, pp. 301–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Ikenoue, Y. Hikiba, F. Kanai et al., “Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors,” Cancer Research, vol. 63, no. 23, pp. 8132–8137, 2003. View at Google Scholar · View at Scopus
  44. K. Fransén, M. Klintenäs, A. Österström, J. Dimberg, H.-J. Monstein, and P. Söderkvist, “Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas,” Carcinogenesis, vol. 25, no. 4, pp. 527–533, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Wong and D. Cunningham, “Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5668–5670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. E. van Cutsem, C.-H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sartore-Bianchi, M. Martini, F. Molinari et al., “PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies,” Cancer Research, vol. 69, no. 5, pp. 1851–1857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. L. A. Aaltonen, P. Peltomäki, J.-P. Mecklin et al., “Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients,” Cancer Research, vol. 54, no. 7, pp. 1645–1648, 1994. View at Google Scholar · View at Scopus
  50. S. M. Lipkin, V. Wang, D. L. Stoler et al., “Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: evidence for somatic mutation in colorectal cancers,” Human Mutation, vol. 17, no. 5, pp. 389–396, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. H. T. Lynch and A. de la Chapelle, “Hereditary colorectal cancer,” The New England Journal of Medicine, vol. 348, no. 10, pp. 919–932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. D. Wheeler, A. Loukola, L. A. Aaltonen, N. J. McC Mortensen, and W. F. Bodmer, “The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers,” Journal of Medical Genetics, vol. 37, no. 8, pp. 588–592, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. J.-P. Issa, “Colon cancer: it's CIN or CIMP,” Clinical Cancer Research, vol. 14, no. 19, pp. 5939–5940, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Popat and R. S. Houlston, “A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis,” European Journal of Cancer, vol. 41, no. 14, pp. 2060–2070, 2005. View at Google Scholar · View at Scopus
  55. A. Walther, R. Houlston, and I. Tomlinson, “Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis,” Gut, vol. 57, no. 7, pp. 941–950, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Jover, A. Payá, C. Alenda et al., “Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis,” The American Journal of Clinical Pathology, vol. 122, no. 3, pp. 389–394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. W. S. Samowitz, K. Curtin, K. N. Ma et al., “Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level,” Cancer Epidemiology, Biomarkers & Prevention, vol. 10, no. 9, pp. 917–923, 2001. View at Google Scholar
  58. S. Ogino, M. Cantor, T. Kawasaki et al., “CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies,” Gut, vol. 55, no. 7, pp. 1000–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Ogino, T. Kawasaki, G. J. Kirkner, P. Kraft, M. Loda, and C. S. Fuchs, “Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample,” Journal of Molecular Diagnostics, vol. 9, no. 3, pp. 305–314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J.-P. J. Issa, “CpG island methylator phenotype in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8681–8686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Toyota, L. Shen, M. Ohe-Toyota, S. R. Hamilton, F. A. Sinicrope, and J.-P. J. Issa, “Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors,” Cancer Research, vol. 60, no. 15, pp. 4044–4048, 2000. View at Google Scholar · View at Scopus
  62. N. M. Gatto, H. Frucht, V. Sundararajan, J. S. Jacobson, V. R. Grann, and A. I. Neugut, “Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study,” Journal of the National Cancer Institute, vol. 95, no. 3, pp. 230–236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. C. D. Johnson, M. H. Chen, A. Y. Toledano et al., “Accuracy of CT colonography for detection of large adenomas and cancers,” The New England Journal of Medicine, vol. 359, no. 12, pp. 1207–1217, 2008. View at Publisher · View at Google Scholar
  64. P. J. Pickhardt, J. R. Choi, I. Hwang et al., “Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults,” The New England Journal of Medicine, vol. 349, no. 23, pp. 2191–2200, 2003. View at Publisher · View at Google Scholar
  65. S. Summerton, E. Little, and M. S. Cappell, “CT colonography: current status and future promise,” Gastroenterology Clinics of North America, vol. 37, no. 1, pp. 161–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Burch, K. Soares-Weiser, D. J. B. St John et al., “Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review,” Journal of Medical Screening, vol. 14, no. 3, pp. 132–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. L. Ouyang, J. J. Chen, R. H. Getzenberg, and R. E. Schoen, “Noninvasive testing for colorectal cancer: a review,” The American Journal of Gastroenterology, vol. 100, no. 6, pp. 1393–1403, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, “Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives,” Genetics in Medicine, vol. 11, no. 1, pp. 35–41, 2009. View at Publisher · View at Google Scholar
  69. T. F. Imperiale, D. F. Ransohoff, S. H. Itzkowitz et al., “Multitarget stool DNA testing for colorectal-cancer screening,” The New England Journal of Medicine, vol. 370, no. 14, pp. 1287–1297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. S. W. An, N. K. Kim, and H. C. Chung, “Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening,” Yonsei Medical Journal, vol. 50, no. 3, pp. 331–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Tao, S. Hundt, U. Haug, and H. Brenner, “Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease,” The American Journal of Gastroenterology, vol. 106, no. 2, pp. 242–253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Ogino and A. Goel, “Molecular classification and correlates in colorectal cancer,” Journal of Molecular Diagnostics, vol. 10, no. 1, pp. 13–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Kambara, L. A. Simms, V. L. J. Whitehall et al., “BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum,” Gut, vol. 53, no. 8, pp. 1137–1144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Hawkins, M. Norrie, K. Cheong et al., “CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability,” Gastroenterology, vol. 122, no. 5, pp. 1376–1387, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. M. van Rijnsoever, F. Grieu, H. Elsaleh, D. Joseph, and B. Iacopetta, “Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands,” Gut, vol. 51, no. 6, pp. 797–802, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Toyota, M. Ohe-Toyota, N. Ahuja, and J.-P. J. Issa, “Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 710–715, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Wang, T. Jatkoe, Y. Zhang et al., “Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1564–1571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Barrier, P.-Y. Boelle, F. Roser et al., “Stage II colon cancer prognosis prediction by tumor gene expression profiling,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4685–4691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. S.-W. Jiang, J. Li, K. Podratz, and S. Dowdy, “Application of DNA methylation biomarkers for endometrial cancer management,” Expert Review of Molecular Diagnostics, vol. 8, no. 5, pp. 607–616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Gray, J. Barnwell, C. McConkey, R. K. Hills, N. S. Williams, and D. J. Kerr, “Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study,” The Lancet, vol. 370, no. 9604, pp. 2020–2029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Ma, P. Zhang, J. Yang, Z. Liu, Z. Yang, and H. Qin, “Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation,” International Journal of Cancer, vol. 130, no. 9, pp. 2077–2087, 2011. View at Publisher · View at Google Scholar
  82. S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3230–3237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Jacobs, W. de Roock, H. Piessevaux et al., “Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 5068–5074, 2009. View at Google Scholar · View at Scopus
  84. J. B. Baker, D. Dutta, D. Watson et al., “Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer,” British Journal of Cancer, vol. 104, no. 3, pp. 488–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. K. E. Bachman, P. Argani, Y. Samuels et al., “The PIK3CA gene is mutated with high frequency in human breast cancers,” Cancer Biology and Therapy, vol. 3, no. 8, pp. 772–775, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Samuels, L. A. Diaz Jr., O. Schmidt-Kittler et al., “Mutant PIK3CA promotes cell growth and invasion of human cancer cells,” Cancer Cell, vol. 7, no. 6, pp. 561–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Frattini, P. Saletti, E. Romagnani et al., “PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients,” British Journal of Cancer, vol. 97, no. 8, pp. 1139–1145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. N. K. Osborn and D. A. Ahlquist, “Stool screening for colorectal cancer: molecular approaches,” Gastroenterology, vol. 128, no. 1, pp. 192–206, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. J. S. Mandel, J. H. Bond, T. R. Church et al., “Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study,” The New England Journal of Medicine, vol. 328, no. 19, pp. 1365–1371, 1993. View at Publisher · View at Google Scholar · View at Scopus
  90. O. Kronborg, C. Fenger, J. Olsen, O. D. Jørgensen, and O. Søndergaard, “Randomised study of screening for colorectal cancer with faecal-occult-blood test,” The Lancet, vol. 348, no. 9040, pp. 1467–1471, 1996. View at Publisher · View at Google Scholar · View at Scopus
  91. J. D. Hardcastle, J. O. Chamberlain, M. H. E. Robinson et al., “Randomised controlled trial of faecal-occult-blood screening for colorectal cancer,” The Lancet, vol. 348, no. 9040, pp. 1472–1477, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Hewitson, P. Glasziou, E. Watson, B. Towler, and L. Irwig, “Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1541–1549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. F. A. Oort, J. S. T. S. Droste, R. W. M. van der Hulst et al., “Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 3, pp. 432–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. L. G. M. van Rossum, A. F. van Rijn, I. P. van Munster et al., “Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests,” Netherlands Journal of Medicine, vol. 67, no. 5, pp. 182–186, 2009. View at Google Scholar · View at Scopus
  95. B. Levin, D. Brooks, R. A. Smith, and A. Stone, “Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers,” CA: A Cancer Journal for Clinicians, vol. 53, no. 1, pp. 44–55, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. W.-D. Chen, Z. J. Han, J. Skoletsky et al., “Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene,” Journal of the National Cancer Institute, vol. 97, no. 15, pp. 1124–1132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Zou, J. J. Harrington, A. M. Shire et al., “Highly methylated genes in colorectal neoplasia: implications for screening,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 12, pp. 2686–2696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Sidransky, T. Tokino, S. R. Hamilton et al., “Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors,” Science, vol. 256, no. 5053, pp. 102–105, 1992. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Sjoblom, S. Jones, L. D. Wood et al., “The consensus coding sequences of human breast and colorectal cancers,” Science, vol. 314, no. 5797, pp. 268–274, 2006. View at Publisher · View at Google Scholar
  100. M. J. Mäkinen, “Colorectal serrated adenocarcinoma,” Histopathology, vol. 50, no. 1, pp. 131–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Takai, S. Kanaoka, K.-I. Yoshida et al., “Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 6, pp. 1888–1893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Link, F. Balaguer, Y. Shen et al., “Fecal microRNAs as novel biomarkers for colon cancer screening,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 7, pp. 1766–1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. A. C. von Roon, L. Karamountzos, S. Purkayastha et al., “Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy,” The American Journal of Gastroenterology, vol. 102, no. 4, pp. 803–813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. P. X. Xing, G. P. Young, D. Ho, M. A. Sinatra, P. B. Hoj, and I. F. McKenzie, “A new approach to fecal occult blood testing based on the detection of haptoglobin,” Cancer, vol. 78, no. 1, pp. 48–56, 1996. View at Publisher · View at Google Scholar
  105. I. K. Quaye, “Haptoglobin, inflammation and disease,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 102, no. 8, pp. 735–742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. G. Y. Locker, S. Hamilton, J. Harris et al., “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5313–5327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Hundt, U. Haug, and H. Brenner, “Blood markers for early detection of colorectal cancer: a systematic review,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 1935–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Jung, M. Fleischhacker, and A. Rabien, “Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1611–1624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Frattini, G. Gallino, S. Signoroni et al., “Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer,” Cancer Letters, vol. 263, no. 2, pp. 170–181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. N. Umetani, J. Kim, S. Hiramatsu et al., “Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats,” Clinical Chemistry, vol. 52, no. 6, pp. 1062–1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. P. Anker, F. Lefort, V. Vasioukhin et al., “K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer,” Gastroenterology, vol. 112, no. 4, pp. 1114–1120, 1997. View at Publisher · View at Google Scholar · View at Scopus
  112. J. B. de Kok, W. W. van Solinge, T. J. M. Ruers et al., “Detection of tumour DNA in serum of colorectal cancer patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 57, no. 7, pp. 601–604, 1997. View at Publisher · View at Google Scholar · View at Scopus
  113. M. S. Kopreski, F. A. Benko, C. Kwee et al., “Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer,” British Journal of Cancer, vol. 76, no. 10, pp. 1293–1299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Li, W.-D. Chen, N. Papadopoulos et al., “Sensitive digital quantification of DNA methylation in clinical samples,” Nature Biotechnology, vol. 27, no. 9, pp. 858–863, 2009. View at Publisher · View at Google Scholar
  115. R. Grützmann, B. Molnar, C. Pilarsky et al., “Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay,” PLoS ONE, vol. 3, no. 11, Article ID e3759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Lofton-Day, F. Model, T. DeVos et al., “DNA methylation biomarkers for blood-based colorectal cancer screening,” Clinical Chemistry, vol. 54, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. R. E. Board, L. Knight, A. Greystoke et al., “DNA methylation in circulating tumour DNA as a biomarker for cancer,” Biomarker Insights, vol. 2, pp. 307–319, 2008. View at Google Scholar
  118. T. deVos, R. Tetzner, F. Model et al., “Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer,” Clinical Chemistry, vol. 55, no. 7, pp. 1337–1346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. C. P. E. Lange, M. Campan, T. Hinoue et al., “Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer,” PLoS ONE, vol. 7, no. 11, Article ID e50266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. R. Douard, S. Moutereau, V. Serru et al., “Immunobead multiplex RT-PCR detection of carcinoembryonic genes expressing cells in the blood of colorectal cancer patients,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 2, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Shen, L. Hu, L. Xia, and Y. Li, “Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients,” Japanese Journal of Clinical Oncology, vol. 38, no. 11, pp. 770–776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Y. Wang, C. S. Yeh, Y. F. Chen et al., “Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer,” International Journal of Molecular Medicine, vol. 17, no. 5, pp. 737–747, 2006. View at Google Scholar · View at Scopus
  123. D. Xu, X.-F. Li, S. Zheng, and W.-Z. Jiang, “Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients,” Journal of Zhejiang University SCIENCE B, vol. 7, no. 6, pp. 445–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. C.-S. Yeh, J.-Y. Wang, C.-H. Wu et al., “Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel,” International Journal of Oncology, vol. 28, no. 2, pp. 411–420, 2006. View at Google Scholar · View at Scopus
  125. S. M. Lledó, E. Garcia-Granero, F. Dasí et al., “Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer,” Colorectal Disease, vol. 6, no. 4, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Douard, V. Le Maire, P. Wind et al., “Carcinoembryonic gene member 2 mRNA expression as a marker to detect circulating enterocytes in the blood of colorectal cancer patients,” Surgery, vol. 129, no. 5, pp. 587–594, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. I. Miyashiro, C. Kuo, K. Huynh et al., “Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes,” Clinical Chemistry, vol. 47, no. 3, pp. 505–512, 2001. View at Google Scholar · View at Scopus
  128. V. Garcia, J. M. García, C. Peña et al., “Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential,” Clinical Cancer Research, vol. 12, no. 7, part 1, pp. 2095–2100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. S. A. Bustin, V. G. Gyselman, N. S. Williams, and S. Dorudi, “Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients,” British Journal of Cancer, vol. 79, no. 11-12, pp. 1813–1820, 1999. View at Publisher · View at Google Scholar · View at Scopus
  130. T. H. K. Schiedeck, C. Wellm, U. J. Roblick, R. Broll, and H.-P. Bruch, “Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzymelinked immunosorbent assay,” Diseases of the Colon & Rectum, vol. 46, no. 6, pp. 818–825, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. X. Chen, Y. Ba, L. Ma et al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases,” Cell Research, vol. 18, no. 10, pp. 997–1006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. Z. Kanaan, H. Roberts, M. R. Eichenberger et al., “A plasma MicroRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer,” Annals of Surgery, vol. 258, no. 3, pp. 400–406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. F. L. Yong, C. W. Law, and C. W. Wang, “Potentiality of a triple microRNA classifier: MiR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer,” BMC Cancer, vol. 13, article 280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. E. K. O. Ng, W. W. S. Chong, H. Jin et al., “Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening,” Gut, vol. 58, no. 10, pp. 1375–1381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Menéndez, D. Padilla, P. Villarejo et al., “Prognostic implications of serum microRNA-21 in colorectal cancer,” Journal of Surgical Oncology, vol. 108, no. 6, pp. 369–373, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen et al., “Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer,” Clinical Cancer Research, vol. 8, no. 4, pp. 156–164, 2002. View at Google Scholar
  137. I. Babel, R. Barderas, R. Díaz-Uriarte, J. L. Martínez-Torrecuadrada, M. Sánchez-Carbayo, and J. I. Casal, “Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays,” Molecular & Cellular Proteomics, vol. 8, no. 10, pp. 2382–2395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. E. S. Leman, R. E. Schoen, A. Magheli, L. J. Sokoll, D. W. Chan, and R. H. Getzenberg, “Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer,” Clinical Cancer Research, vol. 14, no. 5, pp. 1349–1354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. E. S. Leman, R. E. Schoen, J. L. Weissfeld et al., “Initial analyses of Colon Cancer—Specific Antigen (CCSA)-3 and CCSA-4 as colorectal cancer—associated serum markers,” Cancer Research, vol. 67, no. 12, pp. 5600–5605, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. M. S. Kim, J. Louwagie, B. Carvalho et al., “Promoter DNA methylation of oncostatin M receptor-β as a novel diagnostic and therapeutic marker in colon cancer,” PLoS ONE, vol. 4, no. 8, Article ID e6555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. N. G. Hurst, D. D. Stocken, S. Wilson, C. Keh, M. J. O. Wakelam, and T. Ismail, “Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients,” British Journal of Cancer, vol. 97, no. 7, pp. 971–977, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Sastre, M. L. Maestro, J. Puente et al., “Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables,” Annals of Oncology, vol. 19, no. 5, pp. 935–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. S. J. Cohen, C. J. Punt, N. Iannotti et al., “Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3213–3221, 2008. View at Publisher · View at Google Scholar
  144. S. J. Cohen, C. J. A. Punt, N. Iannotti et al., “Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 20, no. 7, pp. 1223–1229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. Y.-H. Uen, C.-Y. Lu, H.-L. Tsai et al., “Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection,” Annals of Surgical Oncology, vol. 15, no. 8, pp. 2120–2128, 2008. View at Publisher · View at Google Scholar · View at Scopus